BeiGene Ltd

BGNE05 Dec 2024
Healthcare
$203.37
-0.03 (-3.29%)
Lowest Today
$199.27
Highest Today
$205.9
Today’s Open
$203.37
Prev. Close
$206.01
52 Week High
$248.16
52 Week Low
$126.97
To Invest in BeiGene Ltd

BeiGene Ltd

Healthcare
BGNE05 Dec 2024
-0.03 (-3.29%)
1M
3M
6M
1Y
5Y
Low
$199.27
Day’s Range
High
$205.9
199.27
52 Week Low
$126.97
52-Week Range
52 Week High
$248.16
126.97
1 Day
-
1 Week
-0.42%
1 month return
-0.95%
3 month return
+8.95%
6 month return
+32.7%
1 Year return
+13.58%
3 Years return
-31.23%
5 Years return
+6.85%
10 Years return
-
Institutional Holdings
Baker Bros Advisors LP
9.94
Capital Research & Mgmt Co - Division 3
6.05
Hillhouse Capital Advisors, Ltd.
4.87
PRIMECAP Management Company
4.68
Baillie Gifford & Co Limited.
3.49
American Funds New Perspective A
2.64
Capital Group New Perspective Comp
2.64

Market Status

Fundamentals
Market Cap
23544.18 mln
PB Ratio
6.37
PE Ratio
0
Enterprise Value
21943.78 mln
Total Assets
5805.28 mln
Volume

Company Financials

Fund house & investment objective

Company Information
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Organisation
BeiGene Ltd
Employees
10600
Industry
Biotechnology
CEO
Mr. John V. Oyler
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step